|Thai HealthBaby is a member of the HealthBanks Biotech family of companies, which for over 20 years has been a leader in pharmaceuticals, stem cell therapy and research with over 70,000 cord blood procedures.|
We were the first family cord blood bank in the world to adopt the optimum methods and technologies of the world’s leading public cord blood programs. We’ve set new standards which few – if any – family cord blood banks have been able to match.
Research is a vital component of cord blood collection and storage. Not only does it keep Thai HealthBaby at the forefront of the latest technologies and practices, it enables us to be part of a larger purpose – to better understand and discover new ways cord blood can be used to treat and cure diseases.
Thai HealthBaby, in connection with its parent company, HealthBanks Biotech, works closely with researchers at a wide range of well known medical institutions, such as UCLA and Johns Hopkins, who are leaders conducting research on the application of stem cells in medical treatments.
Here are some areas where we are putting these words into action:
Human Papilloma Virus (HPV) Vaccine
HPV is a common virus that infects the skin and mucous membranes. There are about 100 types of HPV. Approximately 30 of those are spread through genital contact (typically sexual intercourse). Roughly 12 “low-risk” types of HPV can cause genital warts. In addition, there are approximately 15 “high-risk” types of HPV that can cause cervical cancer. It is estimated that 80 percent of all women and 50 percent of men and women combined will get one or more types of “genital” HPV at some point in their lives. We are in process of filing for an investigational new drug (IND) to start a Phase 1 clinical trial in the U.S for a vaccine for treatment and prevention of HPV.
Stem cells are not only useful when it comes to treating and curing diseases, but are also useful in testing vaccines – vaccines that are used in the treatment and prevention of serious or deadly diseases. As a result, Thai HealthBaby is part of an ongoing research project that utilizes stem cells to test the potency of vaccines for human application.
The success rate for stem cell transplants relates to several factors including the viability (how well the cell will function) of the stem cells, the HLA (DNA) match of the graft and the total number of viable cells that are infused to the patient. We are currently developing new methods to expand stem cells for use in bone marrow transplants.